We are live on ! Find out more
SGTX

Sigilon Therapeutics, Inc. Common Stock

Delisted

SGTX was delisted on the 10th of August, 2023.

33 hedge funds and large institutions have $8.5M invested in Sigilon Therapeutics, Inc. Common Stock in 2022 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 6 increasing their positions, 13 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

11% less funds holding

Funds holding: 3733 (-4)

40% less capital invested

Capital invested by funds: $14.2M → $8.5M (-$5.67M)

54% less repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 13

67% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 6

100% less funds holding in top 10

Funds holding in top 10: 10 (-1)

Holders
33
Holders Change
-4
Holders Change %
-10.81%
% of All Funds
0.57%
Holding in Top 10
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-100%
% of All Funds
New
2
Increased
6
Reduced
13
Closed
6
Calls
$7K
Puts
Net Calls
+$7K
Net Calls Change
+$8K

SGTX Hedge Fund Activity: Q3 2022 in Review

33 of the 5,806 institutional investors tracked by Wall St. Rank reported a position in Sigilon Therapeutics, Inc. Common Stock (SGTX) for Q3 2022, worth a combined $8.5M — down 40% from $14.2M a quarter earlier.

Sellers outnumbered buyers: 6 funds closed out of SGTX and 2 opened new positions — a net loss of 4 holders — while 13 trimmed existing stakes and 6 added.

The largest buyer was Vanguard Group, adding an estimated $38.5K. The largest seller was Millennium Management, cutting an estimated $54.8K.

  • 33 institutional investors held Sigilon Therapeutics, Inc. Common Stock (SGTX) as of Q3 2022, down from 37 in Q2 2022.
  • Funds reported $8.5M of Sigilon Therapeutics, Inc. Common Stock stock for Q3 2022, down 40% quarter-over-quarter.
  • 2 funds opened new Sigilon Therapeutics, Inc. Common Stock positions in Q3 2022 and 6 closed out, a net change of -4 holders.
  • The largest Sigilon Therapeutics, Inc. Common Stock buyer in Q3 2022 was Vanguard Group, an estimated $38.5K added.
  • The largest Sigilon Therapeutics, Inc. Common Stock seller in Q3 2022 was Millennium Management, an estimated $54.8K sold.

Based on aggregated 13F filings for Q3 2022.